Product Pipeline

About Osteoarthritis

Osteoarthritis (OA) is the most common chronic degenerative joint disease, characterized by progressive wear of joint cartilage. Clinical manifestations of OA include, but are not limited to, pain in and around the joint and limited joint motion.

Due to the inability of joint cartilage to self-heal, OA is among the most challenging joint diseases to treat, and currently no cure exists.

The focus of current OA management is to reduce pain and improve function of the affected joints.

Global estimates of OA

Global estimates of OA exceed 100 million sufferers, and symptomatic OA afflicts more than 50 million Americans. Loss of joint function as a result of this condition is a major cause of work disability and reduced quality of life.

MM-II

Moebius’s lead product

MM-II is a novel suspension of large, empty, multilamellar liposomes MM-II which coat cartilage, reduce friction and wear on the joint, and have been shown to decrease cartilage degeneration in animal studies.

A global Phase 2b clinical trial has demonstrated pain relief of up to 26 weeks after a single injection of MM-II in patients with painful knee OA. See our press releases here for more information.

Moebius is currently engaged in clinical development of MM-II in collaboration with Sun Pharmaceuticals Industries Ltd.

MM-II’s MoA (Mechanism of Action)

MM-II’s primary MoA is joint lubrication

It coats the cartilage surface to reduce friction and wear. In addition, by reducing aggrecan degradation on cartilage explants, it demonstrates a protective effect and indirectly reduces inflammation.

Read more about MM-II in our Publications & Presentations.

Future Directions

Moebius has significant research experience in the areas of cartilage repair and joint lubrication, coupled with intricate understanding of liposomal technologies and manufacturing. The team is using this knowledge to develop additional undisclosed assets.

Careers

We invite you to join a team bringing hope to 100+ million OA sufferers throughout the world.
We look forward to reviewing your resume. Please contact us via LinkedIn.